The Chemical and pharmaceutical company Bayer AG, posted a 44% inclination in the fourth-quarter net profit. The company officials have informed that the net profit at the end of the quarter at December was €153 million. At the same time a year earlier the figure was €106 million.

Analysts had expected a net profit of €303 million. But negative currency effects had reduced the firm's earnings during the quarter by €80 million. This augmented net sales and net profit is a clear indication of the strong sales base of health-care sector in US market.

Mean while Bayer is planning to introduce some of the upcoming drugs, including anti-clotting drug, Xarelto for the patients undergoing hip or knee replacement surgery and medicines to prevent stroke in patients with arterial fibrillation and also for the treatment of deep-vein thrombosis etc.

The Chief Executive Officer of Bayer Werner Wenning has anticipated that the sales growth might have to undergo an adjustment of more than 5% in the coming year. The earnings per share are also expected to rise 10% this year and average growth of 10% by 2012.